Enhanced IgG galactosylation has also been reported in patients with inflammatory bowel disease (IBD), CD and UC, treated with AZA/6MP compared to anti-TNFα Ig treatment (155), and in CD patients after VDZ implementation (153), while anti-TNFα therapy in CD resulted in the lower IgG agalactosylation (158). Here, TNF is linked to inflammatory bowel disease.